Thestra

EPLINEX® — an immunohistochemistry assay for the LIMA1-alpha biomarker combined with AI digipathology, identifying which head and neck squamous cell carcinoma cases are aggressive so that the rest can be spared intensive therapy. Univ. of Turku / Turku University Hospital spin-out built on a decade of biomarker research; European patent granted 4/2026, validation published in EMBO Molecular Medicine (2025) across Finnish university hospitals. Founders Doc. Sami Ventelä (TYKS) and Prof. Jukka Westermarck (cancer biology).

The row

Sector

Medtech & Digital Health

Stage

Pre-revenue — No sales yet

Location

Turku

Founded

2023

Research origin

Univ. of Turku

Business ID

3359386-9 · Finnish trade register

Funding

Nordic Science Investments (2024) + Business Finland R&D (2025); amount undisclosed

Links

Where this sits on the map

Thestra is one of 33 companies in Medtech & Digital Health. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗